These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 31743620)

  • 21. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
    Álvarez H; Rava M; Martínez C; Portilla J; Peraire J; Rivero A; Cervero M; Mariño A; Poveda E; Llibre JM;
    HIV Med; 2022 Sep; 23(8):825-836. PubMed ID: 35234328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early HIV viral suppression associated with subsequent 12-month treatment success among people living with HIV in South Africa.
    Violette LR; Thomas KK; Dorward J; Quame-Amaglo J; Garrett N; Drain PK
    HIV Med; 2024 Jun; 25(6):759-765. PubMed ID: 38488308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is HIV-1 viraemia below 20 copies/mL in antiretroviral-treated patients associated with virologic outcome?
    den Oudsten M; van Kampen J; Rijnders B; van de Vijver D; van der Ende M
    Infect Dis (Lond); 2019 Apr; 51(4):259-267. PubMed ID: 30729841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study.
    Kiweewa F; Esber A; Musingye E; Reed D; Crowell TA; Cham F; Semwogerere M; Namagembe R; Nambuya A; Kafeero C; Tindikahwa A; Eller LA; Millard M; Gelderblom HC; Keshinro B; Adamu Y; Maswai J; Owuoth J; Sing'oei VC; Maganga L; Bahemana E; Khamadi S; Robb ML; Ake JA; Polyak CS; Kibuuka H
    PLoS One; 2019; 14(2):e0211344. PubMed ID: 30721233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study.
    Diaz CM; Segura ER; Luz PM; Clark JL; Ribeiro SR; De Boni R; Eksterman L; Moreira R; Currier JS; Veloso VG; Grinsztejn B; Lake JE
    BMC Infect Dis; 2016 Aug; 16():376. PubMed ID: 27503230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy.
    Dorward J; Lessells R; Govender K; Moodley P; Samsunder N; Sookrajh Y; Turner P; Butler CC; Hayward G; Gandhi M; Drain PK; Garrett N
    J Int AIDS Soc; 2023 Sep; 26(9):e26172. PubMed ID: 37735860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
    Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
    Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
    Lopes S; O'Day K; Meyer K; Van Stiphout J; Punekar Y; Radford M; Haas JS
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):270-278. PubMed ID: 31950545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa.
    Onoya D; Hirasen K; van den Berg L; Miot J; Long LC; Fox MP
    Drug Saf; 2018 Dec; 41(12):1343-1353. PubMed ID: 30043384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
    Humphreys EH; Chang LW; Harris J
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.
    Zhong M; Li M; Qi M; Su Y; Yu N; Lv R; Ye Z; Zhang X; Xu X; Cheng C; Chen C; Wei H
    Front Immunol; 2022; 13():1033098. PubMed ID: 36700216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
    Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
    Hoffmann CJ; Maritz J; van Zyl GU
    Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
    Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
    N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.
    Myer L; Phillips TK; McIntyre JA; Hsiao NY; Petro G; Zerbe A; Ramjith J; Bekker LG; Abrams EJ
    HIV Med; 2017 Feb; 18(2):80-88. PubMed ID: 27353189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.